canertinib has been researched along with Benign Neoplasms, Brain in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appleman, VA; Charest, A; Jun, HJ; Sarkaria, JN; Varma, H; Yeo, AT; Zhang, P | 1 |
| Al-Nedawi, K; Garnier, D; Guha, A; Lee, TH; Lee, WJ; Meehan, B; Montermini, L; Rak, J | 1 |
2 other study(ies) available for canertinib and Benign Neoplasms, Brain
| Article | Year |
|---|---|
EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; ErbB Receptors; Glioblastoma; HEK293 Cells; Heterografts; Humans; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Receptor, Platelet-Derived Growth Factor alpha | 2021 |
Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content.
Topics: Animals; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Cetuximab; Culture Media, Conditioned; DNA; ErbB Receptors; Etoposide; Exosomes; Extracellular Vesicles; Glioma; Humans; Mice; Mice, SCID; Morpholines; Neoplasm Transplantation; Neoplasms; Phosphoproteins; Phosphorylation; Proteomics; Quinazolinones; Transfection | 2015 |